[PDF][PDF] Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial
B Escudier, T Eisen, WM Stadler… - Journal of clinical …, 2009 - researchgate.net
B Escudier, T Eisen, WM Stadler, C Szczylik, S Oudard, M Staehler, S Negrier, C Chevreau…
Journal of clinical oncology, 2009•researchgate.netSorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase
III Treatment Approaches in Rena Page 1 Sorafenib for Treatment of Renal Cell Carcinoma:
Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer
Global Evaluation Trial Bernard Escudier, Tim Eisen, Walter M. Stadler, Cezary Szczylik,
Stéphane Oudard, Michael Staehler, Sylvie Negrier, Christine Chevreau, Apurva A. Desai,
Frédéric Rolland, Tomasz Demkow, Thomas E. Hutson, Martin Gore, Sibyl Anderson, Gloria …
III Treatment Approaches in Rena Page 1 Sorafenib for Treatment of Renal Cell Carcinoma:
Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer
Global Evaluation Trial Bernard Escudier, Tim Eisen, Walter M. Stadler, Cezary Szczylik,
Stéphane Oudard, Michael Staehler, Sylvie Negrier, Christine Chevreau, Apurva A. Desai,
Frédéric Rolland, Tomasz Demkow, Thomas E. Hutson, Martin Gore, Sibyl Anderson, Gloria …
Purpose
Mature survival data and evaluation of vascular endothelial growth factor (VEGF) as a prognostic biomarker from the Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET) study in patients with renal cell carcinoma (RCC) are reported.
researchgate.net
